Modulation of murine bone marrow-derived CFU-F and CFU-OB by in vivo bisphosphonate and fluoride treatments.
OBJECTIVE
Bisphosphonates (BPN) have actions on a variety of cell types including: osteoclasts, osteoblasts, osteocytes, and endothelial cells. The objectives of this report are to review the current state of understanding of the effects of BPNs on orthodontic tooth movement and to provide evidence on BPN's in vivo effects on bone marrow-derived osteoprogenitor cells.


METHODS
Mice from the C3H/HeJ (C3H), C57BL/6J (B6), FVB/NJ (FVB), and BALB/cByJ (BALB) strains were treated for 3 weeks with 0, 3, 30, or 150 mcg/kg/week alendronate (ALN) administered subcutaneous alone or in combination with 50 ppm fluoride (F). Bone marrow cells were harvested and subjected to in vitro colony-forming unit fibroblast (CFU-F) and colony-forming unit osteoblasts (CFU-OB) assays.


RESULTS
Baseline differences in CFU-F, CFU-OB/ALP+, and CFU-OB/total were observed among the four strains. Strain-specific responses to ALN and F treatments were observed for CFU-F, CFU-OB/ALP+, and CFU-OB/total. F treatment alone resulted in decreases in CFU-F (p = 0.013), CFU-OB/ALP+ (p = 0.005), and CFU-OB/total (p = 0.003) in the C3H strain. CFU-F (p = 0.036) were decreased by F in the B6 strain. No significant (NS) effects of F were observed for FVB and BALB. ALN treatment resulted in a significant decrease in CFU-F (p = 0.0014) and CFU-OB/total (p = 0.028) in C3H only. ALN treatment had NS effect on CFU-OB/ALP+ in all four strains.


CONCLUSIONS
Genetic factors appear to play a role in ALN's effects on CFU-F and CFU-OB/total but not on CFU-OB/ALP+.
Chou
M-Y
MY
Department of Prosthodontics, School of Dentistry, University of North Carolina, Chapel Hill, NC 27599-7450, USA.
Yan
D
D
Jafarov
T
T
Everett
E T
ET
D019386:Alendronate / Q000008:administration & dosage / Q000494:pharmacology*; D000469:Alkaline Phosphatase / Q000032:analysis; D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000187:drug effects*; D004396:Coloring Agents; D004338:Drug Combinations; D005347:Fibroblasts / Q000187:drug effects*; D005459:Fluorides / Q000008:administration & dosage / Q000494:pharmacology*; D007279:Injections, Subcutaneous; D008297:Male; D008751:Methylene Blue; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D010006:Osteoblasts / Q000187:drug effects* / Q000201:enzymology; D011897:Random Allocation; D013234:Stem Cells / Q000187:drug effects*
D050071:Bone Density Conservation Agents; D004396:Coloring Agents; D004338:Drug Combinations; D000469:Alkaline Phosphatase; D005459:Fluorides; D008751:Methylene Blue; D019386:Alendronate